This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571)

Published on in Vol 8, No 11 (2019): November

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/14335, first published .
Monitoring of Vedolizumab Infusion Therapy (MOVE-IT) Response With Fecal Inflammation Markers, Ultrasound, and Trough Serum Level in Patients With Ulcerative Colitis: Protocol for a Multicentric, Prospective, Noninterventional Study

Monitoring of Vedolizumab Infusion Therapy (MOVE-IT) Response With Fecal Inflammation Markers, Ultrasound, and Trough Serum Level in Patients With Ulcerative Colitis: Protocol for a Multicentric, Prospective, Noninterventional Study

Monitoring of Vedolizumab Infusion Therapy (MOVE-IT) Response With Fecal Inflammation Markers, Ultrasound, and Trough Serum Level in Patients With Ulcerative Colitis: Protocol for a Multicentric, Prospective, Noninterventional Study

Authors of this article:

Jimmi Cording1 Author Orcid Image ;   Margit Blömacher1 Author Orcid Image ;   Berit Inga Wiebe1 Author Orcid Image ;   Jost Langhorst2 Author Orcid Image ;   Torsten Kucharzik3 Author Orcid Image ;   Andreas Sturm4 Author Orcid Image ;   Stefan Schreiber5 Author Orcid Image ;   Ulf Helwig5, 6 Author Orcid Image
Article Authors Cited by (1) Tweetations (1) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.